Clinical trials in Richmond, VA

143 recruiting studies have a site in or near Richmond, VA, Virginia.

Top conditions here

All conditions

Showing 40 of 143 studies

RecruitingPhase 3NCT04047628

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Charlottesville, VA · Richmond, VA · +21 more sites

RecruitingPhase 3NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Sponsor: Merck Sharp & Dohme LLC

Charlottesville, VA · Fairfax, VA · +60 more sites

RecruitingPhase 2NCT07752979

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Sponsor: AbbVie

Arlington, VA · Danville, VA · Newport News, VA · +56 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Fairfax, VA · Falls Church, VA · Richmond, VA · +452 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Bristol, VA · Burke, VA · Charlottesville, VA · +1147 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Charlottesville, VA · Norfolk, VA · Richmond, VA · +112 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Fredericksburg, VA · Lynchburg, VA · Richmond, VA · +278 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Fairfax, VA · Norfolk, VA · Richmond, VA · +51 more sites

RecruitingPhase 3NCT07391774

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Sponsor: National Cancer Institute (NCI)

Fishersville, VA · Lynchburg, VA · Mechanicsville, VA · +200 more sites

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

Richmond, VA · +18 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Arlington, VA · Fairfax, VA · Richmond, VA · +50 more sites

RecruitingPhase 2NCT06958536

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

Sponsor: Sanofi

Richmond, VA · +19 more sites

RecruitingPhase 3NCT06975865

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Sponsor: Sanofi

Richmond, VA · +20 more sites

RecruitingPhase 3NCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Sponsor: Hoffmann-La Roche

Arlington, VA · Fairfax, VA · Richmond, VA · +65 more sites

RecruitingPhase 3NCT07181109

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Sponsor: Alnylam Pharmaceuticals

Arlington, VA · Danville, VA · Fairfax, VA · +270 more sites

RecruitingPhase 3NCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Richmond, VA · +55 more sites

RecruitingPhase 2NCT07697456

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Sponsor: AbbVie

Lansdowne Town Center, VA · Richmond, VA · +58 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Charlottesville, VA · Richmond, VA · +223 more sites

RecruitingPhase 3NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE

Fairfax, VA · Fredericksburg, VA · Richmond, VA · +33 more sites

RecruitingPhase 3NCT07064473

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Sponsor: Boehringer Ingelheim

Falls Church, VA · Manassas, VA · Norfolk, VA · +205 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Charlottesville, VA · Fairfax, VA · Richmond, VA · +46 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

Richmond, VA · +11 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Fairfax, VA · Midlothian, VA · Richmond, VA · +43 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Richmond, VA · +86 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Richmond, VA · +134 more sites

RecruitingNot applicableNCT06898515

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Sponsor: Reprieve Cardiovascular, Inc

Falls Church, VA · Richmond, VA · +33 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Fairfax, VA · Richmond, VA · +50 more sites

RecruitingPhase 2NCT06977581

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Sponsor: Pfizer

Richmond, VA · +35 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Blacksburg, VA · Low Moor, VA · Quinton, VA · +238 more sites

RecruitingPhase 3NCT07179380

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Sponsor: Insmed Incorporated

Richmond, VA · +18 more sites

RecruitingNot applicableNCT06911632

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Sponsor: Tempus AI

Richmond, VA · +39 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Charlottesville, VA · Richmond, VA · +26 more sites

RecruitingPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Sponsor: SWOG Cancer Research Network

Midlothian, VA · Richmond, VA · +331 more sites

RecruitingNot applicableNCT06374238

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

Sponsor: University of Pittsburgh

Richmond, VA · +13 more sites

RecruitingPhase 2NCT06699849

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Sponsor: CSL Behring

Richmond, VA · +19 more sites

RecruitingPhase 2NCT07186101

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Sponsor: Eli Lilly and Company

Richmond, VA · Roanoke, VA · +37 more sites

RecruitingPhase 3NCT07222800

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Sponsor: Pfizer

Arlington, VA · Blacksburg, VA · Fairfax, VA · +251 more sites

RecruitingPhase 3NCT07794579

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Sponsor: Eli Lilly and Company

Danville, VA · Richmond, VA · +78 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Charlottesville, VA · Fairfax, VA · Richmond, VA · +84 more sites

RecruitingPhase 3NCT06672549

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Sponsor: Eli Lilly and Company

Richmond, VA · +49 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.